| Literature DB >> 15378712 |
Oleg Krokhin1, Werner Ens, Kenneth G Standing, John Wilkins, Hélène Perreault.
Abstract
The identification of glycosylation sites in proteins is often possible through a combination of proteolytic digestion, separation, mass spectrometry (MS) and tandem MS (MS/MS). Liquid chromatography (LC) in combination with MS/MS has been a reliable method for detecting glycopeptides in digestion mixtures, and for assigning glycosylation sites and glycopeptide sequences. Direct interfacing of LC with MS relies on electrospray ionization, which produces ions with two, three or four charges for most proteolytic peptides and glycopeptides. MS/MS spectra of such glycopeptide ions often lead to ambiguous interpretation if deconvolution to the singly charged level is not used. In contrast, the matrix-assisted laser desorption/ionization (MALDI) technique usually produces singly charged peptide and glycopeptide ions. These ions require an extended m/z range, as provided by the quadrupole-quadrupole time-of-flight (QqTOF) instrument used in these experiments, but the main advantages of studying singly charged ions are the simplicity and consistency of the MS/MS spectra. A first aim of the present study is to develop methods to recognize and use glycopeptide [M+H]+ ions as precursors for MS/MS, and thus for glycopeptide/glycoprotein identification as part of wider proteomics studies. Secondly, this article aims at demonstrating the usefulness of MALDI-MS/MS spectra of N-glycopeptides. Mixtures of diverse types of proteins, obtained commercially, were prepared and subjected to reduction, alkylation and tryptic digestion. Micro-column reversed-phase separation allowed deposition of several fractions on MALDI plates, followed by MS and MS/MS analysis of all peptides. Glycopeptide fractions were identified after MS by their specific m/z spacing patterns (162, 203, 291 u) between glycoforms, and then analyzed by MS/MS. In most cases, MS/MS spectra of [M+H]+ ions of glycopeptides featured peaks useful for determining sugar composition, peptide sequence, and thus probable glycosylation site. Peptide-related product ions could be used in database search procedures and allowed the identification of the glycoproteins. Copyright 2004 John Wiley & Sons, Ltd.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15378712 PMCID: PMC7169070 DOI: 10.1002/rcm.1585
Source DB: PubMed Journal: Rapid Commun Mass Spectrom ISSN: 0951-4198 Impact factor: 2.419
Scheme 1Fragmentation pattern observed in the MS/MS spectra of precursor ions of glycopeptides generated by MALDI. The tryptic peptide chain is represented by a vertical dashed line. The first N‐acetylglucosamine residue of a glycan attached to asparagine (Asn) is shown, with corresponding fragment ions observed.
Figure 1Portions of MALDI spectra showing (a) high‐mannose glycosylated forms of GGFHNTTALLIQYENYR, corresponding to residues 384–400 of glucose oxidase, and (b) complex glycosylated forms of LDAPTNLQFVNETDSTVLVR, i.e. residues 997–1016 of human fibronectin.
Detection of glycopeptides from various glycoproteins and identification by MS/MS and ‘SonarMS/MS’ search
| Peptide sequence Calculated | [Peptide+H]+ | [Glycopeptide+H]+ | Sonar score | Glycan composition |
|---|---|---|---|---|
| fr.56 | ||||
|
| 2038.867 | 3255.291 | 4.2 × 10−3 | (GlcNAc)2(Man)5 |
| 2038.863 | 3417.333 | (GlcNAc)2(Man)6 | ||
| Bovine lactoferrin (545–562) | 3579.391 | (GlcNAc)2(Man)7 | ||
| 3741.441 | (GlcNAc)2(Man)8 | |||
| 3903.500 | (GlcNAc)2(Man)9 | |||
| fr.63 | ||||
| cglvpvlaeny | 1476.767 | 3099.334 | 2.1 × 10−9 | (GlcNAc)4(Man)3(Gal)2 |
| 1476.752 | 3390.443 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | ||
| Human transferrin (421–433) | 3681.534 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | ||
| fr.70 | ||||
| Previous fragments −17 | 1459.739 | 3082.328 | (GlcNAc)4(Man)3(Gal)2 | |
| 3373.415 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | |||
| 3664.514 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | |||
| fr.73 | ||||
| dqcivdditynv | 2196.986 | 3819.582 | 5.5 × 10−15 | (GlcNAc)4(Man)3(Gal)2 |
| 2196.987 | 4110.676 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | ||
| Human fibronectin 516–533 | 4401.788 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | ||
| fr.74 | ||||
| ldaptnlqfv | 2232.145 | 3854.731 | 3.4 × 10−2 | (GlcNAc)4(Man)3(Gal)2 |
| 2232.151 | 4145.851 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | ||
| Human fibronectin 997–1016 | 4436.932 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | ||
| fr.74 | ||||
| No identification | 3203.39 | 4825.975 | — | (GlcNAc)4(Man)3(Gal)2 |
| 5117.020 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | |||
| fr.76,77. | ||||
| qqqhlfgs | 2515.151 | 4137.763 | Manual | (GlcNAc)4(Man)3(Gal)2 |
| 2515.125 | 4428.844 | sequencing | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | |
| Human transferrin 622–642 | 4719.939 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | ||
| fr.78 | ||||
| Previous fragment −17 | 2498.101 | 4120.693 | — | (GlcNAc)4(Man)3(Gal)2 |
| 4411.794 | (GlcNAc)4(Man)3(Gal)2(NeuAc)1 | |||
| 4702.828 | (GlcNAc)4(Man)3(Gal)2(NeuAc)2 | |||
| fr.72 | ||||
| ggfh | 1996.986 | 3375.468 | (GlcNAc)2(Man)6 | |
| 1996.988 | 3537.53 | 1.1 × 10−12 | (GlcNAc)2(Man)7 | |
| Glucose oxidase asp. niger 384–400 | 3699.589 | (GlcNAc)2(Man)8 | ||
| 3861.625 | (GlcNAc)2(Man)9 | |||
| 4023.727 | (GlcNAc)2(Man)10 | |||
| 4185.751 | (GlcNAc)2(Man)11 | |||
| fr.73 | ||||
| Same precursor ion | 1996.986 | 3213.423 | (GlcNAc)2(Man)5 | |
| 3375.476 | (GlcNAc)2(Man)6 | |||
| 3537.545 | (GlcNAc)2(Man)7 | |||
| 3699.563 | (GlcNAc)2(Man)8 | |||
| 3861.626 | (GlcNAc)2(Man)9 | |||
| fr.85 | ||||
| itsagagqgqaawfatf | 2854.590 | 4070.732 | 9.1 × 10−17 | (GlcNAc)2(Man)5 |
| 2854.596 | 4232.762 | (GlcNAc)2(Man)6 | ||
| Glucose oxidase asp. niger 338–364 | 4394.839 | (GlcNAc)2(Man)7 | ||
| fr.101 | ||||
| vvhavevalatfnaes | No MS/MS | 5004.344 | No MS/MS | (GlcNAc)5(Man)3(Gal)3 |
| 3016.574 | 5925.438 | (GlcNAc)5(Man)3(Gal)3(NeuAc)1 | ||
| Bovine fetuin 160–187 | ||||
| fr.67 | ||||
| lcpdcpllapl | No MS/MS | 3728.554 | No MS/MS | (GlcNAc)5(Man)3(Gal)3 |
| 1740.841 | 4019.684 | (GlcNAc)5(Man)3(Gal)3(NeuAc)1 | ||
| Bovine fetuin 145–159 | 4310.732 | (GlcNAc)5(Man)3(Gal)3(NeuAc)2 | ||
| 4601.827 | (GlcNAc)5(Man)3(Gal)3(NeuAc)3 |
These assignments were added after the search and are based on knowledge of the protein sequence.
Figure 2MALDI‐MS/MS spectra of five high‐mannose glycoforms of GGFHNTTALLIQYENYR, corresponding to residues 384–400 of glucose oxidase.
Figure 3Detail of Fig. 2(b), with peaks labeled according to the fragmentation of the peptide.
Figure 4MALDI‐MS/MS spectra of three complex glycoforms of DQCIVDDITYNVNDTFHK, corresponding to residues 516–533 of human fibronectin.
Figure 5Detail of Fig. 4(a), with peaks labeled according to the fragmentation of the peptide; for a complete list of the fragments detected, see Table 2.
MS/MS peaks assignments for the peptide DQCIVDDITYNVNDTFHK from human fibronectin. Corresponding MS/MS spectra are shown in Fig. 4(a) (glycosylated peptide, m/z 3819.582) and the expanded section below m/z 2197 in Fig. 5
| Residue | b (calc.), u. | b (meas.) u. | b+83 | b+203 | y (calc.), u. | y (meas.), u. | y+83 | y+203 |
|---|---|---|---|---|---|---|---|---|
| D |
| — | — | — |
| 2196.991 | 2280.021 | 2400.057 |
| Q |
| 244.094 | — | — |
| 2081.959 | — | — |
| C |
| 404.127 | — | — |
| 1953.891 | — | — |
| I |
| 517.205 | — | — |
| — | — | — |
| V |
| 616.284 | — | — |
| 1680.787 | — | 1883.889 |
| D |
| 731.304 | — | — |
| 1581.700 | — | 1784.770 |
| D |
| 846.344 | — | — |
| 1466.689 | 1549.721 | 1669.777 |
| I |
| 959.418 | — | — |
| 1351.666 | 1434.696 | 1554.747 |
| T |
| 1060.464 | — | — |
| 1238.575 | 1321.607 | 1441.652 |
| Y |
| 1223.545 | — | — |
| 1137.525 | 1220.579 | 1340.61 |
| N |
| 1337.556 | — | — |
| 974.474 | 1057.495 | 1177.548 |
| V |
| 1436.619 | — |
| 860.419 | — | 1063.509 | |
|
|
| — | 1633.737 | 1753.78 |
| 761.364 | 844.393 | 964.431 |
| D |
| 1665.742 | 1748.749 | 1868.797 |
| 647.322 | — | — |
| T |
| 1766.775 | — | 1969.9 |
| 532.289 | — | — |
| F |
| 1913.831 | — | — |
| 431.234 | — | — |
| H |
| 2050.867 | 2133.942 | 2254.001 |
| 284.165 | — | — |
| K |
| — | — | — |
| — | — | — |
Figure 6Glycosylation profile of peptide QQQHLFGSNVTDCSGNFCLFR, i.e. residues 622–642 of human transferrin, according to order of elution in reversed‐phase HPLC. In (c), a global m/z decrease by 17 u denotes the formation of pyroglutamic acid at the N‐terminal of the peptide.22
Figure 7MALDI‐MS/MS spectra of two N‐glycoforms of NVTR, a short peptide from human integrin β1.